Processa Acquires Vidya Therapeutics with $200M PIPE to Advance BTK Inhibitor
PCSA sits 36% above its 52-week low of $1.67 on elevated volume (2.1× avg).
Summary
Processa Pharmaceuticals is acquiring Vidya Therapeutics and securing approximately $200 million in a concurrent private placement. The deal brings in VT-7208, a BTK inhibitor targeting multiple disease areas, transforming the pipeline. This follows a going concern warning in May and an urgent need for capital — the PIPE directly addresses the cash burn. The reverse merger effectively recapitalizes the company and shifts its strategic focus. With a market cap near $8.4 million, the $200 million financing is highly dilutive but provides a lifeline. The 8-K filed today confirms the transaction's completion.
At the time of this announcement, PCSA was trading at $2.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.4M. The 52-week trading range was $1.67 to $14.24. This news item was assessed with positive market sentiment and an importance score of 10 out of 10. Source: Reuters.